AI Summary & Key Takeaways
AI InsightThe aim of the case presentation is to discuss the causes and management of these complications after intravitreal dexamethasone implantation.
📌 3 Key Takeaways
Özet
Ozurdex® (Allergan, Inc, Irvine, CA, USA) is an intravitreal sustained-release dexamethasone implant known to be effective in the treatment of macular edema. Common adverse effects of Ozurdex implantation include increased intraocular pressure and cataract progression; however other ocular complications, such as retinal hemorrhage, extra-macular hole, macular hole, desegmentation of the implant, migration of the implant into the anterior chamber might develop. Retinal injury with desegmantation of the implant has not been reported in the literature yet. A 68-year-old woman presented with complaints of decreased visual acuity in her right eye for approximately 1 month. Her medical history included diabetes mellitus that had been present for 10 years. In ophthalmologic examination, her corrected visual acuity was 1/10 in the right eye and 8/10 in the left eye. The patient was diagnosed with macular edema associated with diabetic retinopathy and intravitreal anti-vascular endothelial growth factor injection was performed in the right eye. In spite of three doses intravitreal anti-vascular endothelial growth factor injection, her best corrected visual acuity and cystoid macular edema did not improve. Therefore, intravitreal dexamethasone implant was injected in the right eye due to persistent macular edema. At one month follow up after injection, fundus examination reveled two pieced and one of the pieces was located on the retina. Laser photocoagulation was performed around the dexamethasone implant location. The aim of the case presentation is to discuss the causes and management of these complications after intravitreal dexamethasone implantation.